US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Neumora Therapeutics, Inc.

2.33

-0.1600-6.43%

Post-market: 2.370.0400+1.72%19:10 EDT

Volume:954.53K

Turnover:2.23M

Market Cap:396.10M

PE:-1.59

High:2.49

Open:2.49

Low:2.28

Close:2.49

52wk High:3.65

52wk Low:0.6110

Shares:170.00M

Float Shares:86.06M

Volume Ratio:1.35

T/O Rate:1.11%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.4632

EPS(LYR):-1.5296

ROE:-104.35%

ROA:-56.71%

PB:3.00

PE(LYR):-1.52

Loading ...

Overview Company News Filings

Neumora Therapeutics Unveils Pipeline Advancements Targeting Major Brain Disorders

Neumora Therapeutics Q3 EPS $(0.35) Misses $(0.33) Estimate

Neumora Therapeutics Inc - on-Track to Report Data From Phase 1B Study of Nmra-511 in Alzheimer's Disease Agitation Around Year End

THOMSON REUTERS

Neumora Therapeutics Inc - Expects Cash, Cash Equivalents & Marketable Securities as of Sept 30, 2025, Will Fund Operating Plan Into 2027

THOMSON REUTERS

Neumora Therapeutics Inc - Drawn Additional $40 Mln From Existing Venture Debt Facility With K2 Healthventures

THOMSON REUTERS

Neumora Therapeutics to Join Stifel Healthcare Conference

Neumora Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview

Major Stakeholders Make Bold Moves in Neumora Therapeutics!

Neumora Director Kristina Burow Reports Acquisition of Common Shares

ARCH Venture Partners X Reports Acquisition of Neumora Therapeutics Common Shares

Guggenheim upgrades Neumora Therapeutics, Inc. (NMRA) to a Buy

Neumora Therapeutics price target raised to $8 from $6 at Needham

Neumora Therapeutics Raised to Buy From Neutral by Guggenheim

Neumora Therapeutics' Potential Obesity Drug Shows Weight Loss in Preclinical Mice Studies

MT Newswires Live

Neumora Therapeutics Begins Dosing Study of Investigational Schizophrenia Treatment

MT Newswires Live

Neumora Therapeutics initiates Phase 1 clinical study of NMRA-988

BRIEF-Neumora Therapeutics Announces Initiation Of Phase 1 Clinical Study Of M4 Positive Allosteric Modulator NMRA-898

Neumora Therapeutics Inc - Plans M4 Franchise Update by Mid-2026

THOMSON REUTERS

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator Nmra-898

THOMSON REUTERS

Neumora Reports Positive Preclinical Results for NMRA-215

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NMRA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"NMRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NMRA\",,,,,undefined,":{"symbol":"NMRA","market":"US","secType":"STK","nameCN":"Neumora Therapeutics, Inc.","latestPrice":2.33,"timestamp":1774641600000,"preClose":2.49,"halted":0,"volume":954525,"hourTrading":{"tag":"盘后","latestPrice":2.37,"preClose":2.33,"latestTime":"19:10 EDT","volume":14160,"amount":32995.817,"timestamp":1774653023560,"change":0.04,"changeRate":0.017167,"amplitude":0.017167},"delay":0,"changeRate":-0.06425702811244985,"floatShares":86062982,"shares":170000000,"eps":-1.463171,"marketStatus":"Market Closed","change":-0.16,"latestTime":"03-27 16:00:00 EDT","open":2.49,"high":2.49,"low":2.28,"amount":2233706.8611,"amplitude":0.084337,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.463171,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1694750400000,"exchange":"NASDAQ","adjPreClose":2.49,"preHourTrading":{"tag":"盘前","latestPrice":2.57,"preClose":2.49,"latestTime":"08:00 EDT","volume":20,"amount":51.4,"timestamp":1774612801211,"change":0.08,"changeRate":0.032129,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":2.37,"preClose":2.33,"latestTime":"19:10 EDT","volume":14160,"amount":32995.817,"timestamp":1774653023560,"change":0.04,"changeRate":0.017167,"amplitude":0.017167},"volumeRatio":1.354479,"impliedVol":1.7624,"impliedVolPercentile":0.6534},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NMRA\",,,,,undefined,":{"symbol":"NMRA","floatShares":86062982,"roa":"-56.71%","roe":"-104.35%","lyrEps":-1.529624,"volumeRatio":1.354479,"shares":170000000,"dividePrice":0,"high":2.49,"amplitude":0.084337,"preClose":2.49,"low":2.28,"week52Low":0.611,"pbRate":"3.00","week52High":3.65,"institutionHeld":0,"latestPrice":2.33,"eps":-1.463171,"divideRate":0,"volume":954525,"delay":0,"ttmEps":-1.463171,"open":2.49,"prevYearClose":1.79,"prevWeekClose":2.51,"prevMonthClose":3.49,"prevQuarterClose":1.79,"fiveDayClose":2.51,"twentyDayClose":3.49,"sixtyDayClose":1.77,"earningDate":1774800000000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NMRA\",params:#limit:5,,,undefined,":[{"date":"2026-03-30","symbol":"NMRA","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":"2025/12","expectedEps":-0.34,"defaultRemindTime":1774857600000,"name":null,"time":"","dateTimestamp":1774843200000,"actualEps":null},{"market":"US","date":"2025-11-06","symbol":"NMRA","fiscalQuarterEnding":"2025/09","expectedEps":-0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-0.35},{"market":"US","date":"2025-08-06","symbol":"NMRA","fiscalQuarterEnding":"2025/06","expectedEps":-0.38,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"post","actualEps":-0.33},{"market":"US","date":"2025-05-12","symbol":"NMRA","fiscalQuarterEnding":"2025/03","expectedEps":-0.4,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"post","actualEps":-0.42},{"market":"US","date":"2024-11-12","symbol":"NMRA","fiscalQuarterEnding":"2024/09","expectedEps":-0.38,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NMRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NMRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.4444,"hold":0.1111,"sell":0.1111,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4444,"analysts":9,"updateTime":1771387200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NMRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NMRA","date":"2026-03-26","current":-1.592432,"percent":0.557756,"low":-19.620035,"twenty":-9.780792,"median":-2.509914,"eighty":-1.034219,"high":-0.385538,"avg":-5.4006,"sd":5.110972,"marketCap":424846102},"quantilePoints":[{"date":"2023-09-15","current":-19.620035,"twenty":-19.620035,"median":-19.620035,"eighty":-19.620035,"marketCap":2583134632},{"date":"2023-09-22","current":-12.753675,"twenty":-18.754446,"median":-15.453663,"eighty":-12.753675,"marketCap":1679123396},{"date":"2023-09-28","current":-13.691957,"twenty":-17.415667,"median":-13.628246,"eighty":-12.772209,"marketCap":1802655635},{"date":"2023-10-05","current":-13.813351,"twenty":-16.65135,"median":-13.723658,"eighty":-12.773914,"marketCap":1818638110},{"date":"2023-10-13","current":-11.180579,"twenty":-14.994038,"median":-13.691957,"eighty":-12.763183,"marketCap":1472012710},{"date":"2023-10-20","current":-11.493728,"twenty":-13.94093,"median":-13.080265,"eighty":-11.639864,"marketCap":1513241282},{"date":"2023-10-27","current":-14.254079,"twenty":-14.080107,"median":-13.080265,"eighty":-11.690896,"marketCap":1876663508},{"date":"2023-11-03","current":-10.734234,"twenty":-13.848145,"median":-12.776843,"eighty":-11.493728,"marketCap":1667466680},{"date":"2023-11-10","current":-10.420012,"twenty":-13.826354,"median":-12.7442,"eighty":-11.403032,"marketCap":1618655149},{"date":"2023-11-17","current":-11.79624,"twenty":-13.813351,"median":-12.154821,"eighty":-11.403032,"marketCap":1832439792},{"date":"2023-11-24","current":-11.717599,"twenty":-13.766958,"median":-11.806071,"eighty":-11.438475,"marketCap":1820223526},{"date":"2023-12-01","current":-12.041995,"twenty":-13.704638,"median":-11.815901,"eighty":-11.48267,"marketCap":1870615621},{"date":"2023-12-08","current":-12.26809,"twenty":-13.59002,"median":-11.825731,"eighty":-11.493283,"marketCap":1905737383},{"date":"2023-12-15","current":-14.381583,"twenty":-13.717318,"median":-11.894542,"eighty":-11.493728,"marketCap":2234049513},{"date":"2023-12-22","current":-13.75245,"twenty":-13.821153,"median":-12.041995,"eighty":-11.521564,"marketCap":2136319390},{"date":"2023-12-29","current":-16.848963,"twenty":-14.008036,"median":-12.137729,"eighty":-11.563317,"marketCap":2617334836},{"date":"2024-01-05","current":-16.111698,"twenty":-14.24211,"median":-12.26809,"eighty":-11.573312,"marketCap":2502807349},{"date":"2024-01-12","current":-14.991056,"twenty":-14.660761,"median":-12.728927,"eighty":-11.585874,"marketCap":2328725569},{"date":"2024-01-19","current":-14.411074,"twenty":-14.428768,"median":-12.751722,"eighty":-11.613398,"marketCap":2238630612},{"date":"2024-01-26","current":-14.843603,"twenty":-15.020547,"median":-12.776843,"eighty":-11.648787,"marketCap":2305820071},{"date":"2024-02-02","current":-14.991056,"twenty":-15.264335,"median":-13.370218,"eighty":-11.652719,"marketCap":2328725569},{"date":"2024-02-09","current":-17.1537,"twenty":-15.346909,"median":-13.691957,"eighty":-11.671529,"marketCap":2664672864},{"date":"2024-02-16","current":-18.490607,"twenty":-15.539581,"median":-13.783396,"eighty":-11.691031,"marketCap":2872349373},{"date":"2024-02-23","current":-18.500437,"twenty":-15.932789,"median":-13.819852,"eighty":-11.69454,"marketCap":2873876407},{"date":"2024-03-01","current":-17.330643,"twenty":-16.668088,"median":-13.939224,"eighty":-11.709735,"marketCap":2692159461},{"date":"2024-03-08","current":-12.297819,"twenty":-16.990518,"median":-13.97363,"eighty":-11.717599,"marketCap":2901363004},{"date":"2024-03-15","current":-10.189453,"twenty":-16.81554,"median":-13.826354,"eighty":-11.69454,"marketCap":2403946708},{"date":"2024-03-22","current":-9.414974,"twenty":-16.668088,"median":-13.783396,"eighty":-11.650753,"marketCap":2221227691},{"date":"2024-03-28","current":-8.492333,"twenty":-16.613039,"median":-13.722203,"eighty":-11.579976,"marketCap":2003553733},{"date":"2024-04-05","current":-9.246609,"twenty":-16.364935,"median":-13.534996,"eighty":-11.491504,"marketCap":2181506166},{"date":"2024-04-12","current":-9.435178,"twenty":-16.111698,"median":-12.865966,"eighty":-11.216259,"marketCap":2225994275},{"date":"2024-04-19","current":-7.105005,"twenty":-15.954415,"median":-12.753675,"eighty":-10.606446,"marketCap":1676248365},{"date":"2024-04-26","current":-6.123304,"twenty":-15.846283,"median":-12.728927,"eighty":-10.162515,"marketCap":1444640411},{"date":"2024-05-03","current":-6.231441,"twenty":-15.669339,"median":-12.297819,"eighty":-9.792112,"marketCap":1470152824},{"date":"2024-05-10","current":-6.135514,"twenty":-15.610358,"median":-12.155389,"eighty":-9.435178,"marketCap":1558549450},{"date":"2024-05-17","current":-6.047595,"twenty":-15.433415,"median":-12.120637,"eighty":-9.273547,"marketCap":1536216091},{"date":"2024-05-24","current":-5.846636,"twenty":-15.423584,"median":-11.91675,"eighty":-8.957021,"marketCap":1485168412},{"date":"2024-05-31","current":-6.085275,"twenty":-15.399992,"median":-11.884712,"eighty":-8.469435,"marketCap":1545787530},{"date":"2024-06-07","current":-6.235993,"twenty":-15.362637,"median":-11.806071,"eighty":-7.09423,"marketCap":1584073290},{"date":"2024-06-14","current":-6.248553,"twenty":-15.342977,"median":-11.75692,"eighty":-6.904314,"marketCap":1587263770},{"date":"2024-06-21","current":-5.557759,"twenty":-15.335113,"median":-11.717599,"eighty":-6.419582,"marketCap":1411787373},{"date":"2024-06-28","current":-5.777557,"twenty":-15.335113,"median":-11.707769,"eighty":-6.279953,"marketCap":1467620772},{"date":"2024-07-05","current":-6.129234,"twenty":-15.228947,"median":-11.690896,"eighty":-6.264891,"marketCap":1556954210},{"date":"2024-07-12","current":-7.253346,"twenty":-15.12278,"median":-11.653703,"eighty":-6.277441,"marketCap":1842502165},{"date":"2024-07-15","current":-6.939348,"twenty":-15.110984,"median":-11.648787,"eighty":-6.278697,"marketCap":1762740166},{"date":"2024-08-02","current":-7.931581,"twenty":-15.099188,"median":-11.648787,"eighty":-6.279953,"marketCap":2014788082},{"date":"2024-08-09","current":-6.56038,"twenty":-15.040207,"median":-11.579976,"eighty":-6.279953,"marketCap":1798711865},{"date":"2024-08-16","current":-6.881395,"twenty":-14.991056,"median":-11.493728,"eighty":-6.279953,"marketCap":1886727125},{"date":"2024-08-23","current":-6.712133,"twenty":-14.991056,"median":-11.447336,"eighty":-6.393648,"marketCap":1840319079},{"date":"2024-08-30","current":-6.54287,"twenty":-14.922244,"median":-11.299816,"eighty":-6.436952,"marketCap":1793911032},{"date":"2024-09-06","current":-6.297731,"twenty":-14.859331,"median":-10.957407,"eighty":-6.374465,"marketCap":1726699379},{"date":"2024-09-13","current":-6.904742,"twenty":-14.68632,"median":-10.606446,"eighty":-6.374465,"marketCap":1893128235},{"date":"2024-09-20","current":-7.430039,"twenty":-14.481851,"median":-10.304733,"eighty":-6.410301,"marketCap":2037153206},{"date":"2024-09-27","current":-7.634321,"twenty":-14.416972,"median":-9.973946,"eighty":-6.432454,"marketCap":2093162917},{"date":"2024-10-04","current":-7.905725,"twenty":-14.387481,"median":-9.835887,"eighty":-6.454177,"marketCap":2167575819},{"date":"2024-10-11","current":-8.988421,"twenty":-14.365855,"median":-9.536197,"eighty":-6.471402,"marketCap":2464427288},{"date":"2024-10-18","current":-9.898936,"twenty":-14.275648,"median":-9.492422,"eighty":-6.494727,"marketCap":2714070572},{"date":"2024-10-25","current":-7.587628,"twenty":-14.23812,"median":-9.435178,"eighty":-6.5109,"marketCap":2080360698},{"date":"2024-10-31","current":-7.126534,"twenty":-14.186945,"median":-9.414974,"eighty":-6.517189,"marketCap":1953938778},{"date":"2024-11-08","current":-7.599301,"twenty":-14.11026,"median":-9.329429,"eighty":-6.519524,"marketCap":2083561252},{"date":"2024-11-15","current":-6.430581,"twenty":-14.036864,"median":-9.246609,"eighty":-6.508113,"marketCap":1888648838},{"date":"2024-11-22","current":-5.330396,"twenty":-14.008036,"median":-9.078889,"eighty":-6.434404,"marketCap":1565526710},{"date":"2024-11-29","current":-5.467919,"twenty":-13.980511,"median":-8.972721,"eighty":-6.336098,"marketCap":1605916976},{"date":"2024-12-06","current":-5.313893,"twenty":-13.902792,"median":-8.614876,"eighty":-6.276185,"marketCap":1560679878},{"date":"2024-12-13","current":-5.819979,"twenty":-13.839429,"median":-8.495238,"eighty":-6.248553,"marketCap":1709316057},{"date":"2024-12-20","current":-5.775971,"twenty":-13.821153,"median":-8.377845,"eighty":-6.222869,"marketCap":1696391172},{"date":"2024-12-27","current":-6.238049,"twenty":-13.812967,"median":-8.200475,"eighty":-6.175381,"marketCap":1832102465},{"date":"2025-01-03","current":-1.083682,"twenty":-13.811432,"median":-8.147945,"eighty":-6.157876,"marketCap":318275296},{"date":"2025-01-10","current":-1.303719,"twenty":-13.766574,"median":-7.931581,"eighty":-6.140538,"marketCap":382899721},{"date":"2025-01-17","current":-1.193701,"twenty":-13.753032,"median":-7.891133,"eighty":-6.119668,"marketCap":350587508},{"date":"2025-01-24","current":-1.1882,"twenty":-13.716154,"median":-7.812392,"eighty":-6.085275,"marketCap":348971898},{"date":"2025-01-31","current":-1.056178,"twenty":-13.615504,"median":-7.634321,"eighty":-6.067691,"marketCap":310197242},{"date":"2025-02-07","current":-1.07268,"twenty":-13.546812,"median":-7.564281,"eighty":-5.978405,"marketCap":315044074},{"date":"2025-02-14","current":-0.929656,"twenty":-13.337262,"median":-7.53602,"eighty":-5.966304,"marketCap":273038198},{"date":"2025-02-21","current":-0.940658,"twenty":-13.1053,"median":-7.470895,"eighty":-5.920328,"marketCap":276269419},{"date":"2025-02-28","current":-0.852643,"twenty":-12.883791,"median":-7.424202,"eighty":-5.847483,"marketCap":250419649},{"date":"2025-03-07","current":-1.009931,"twenty":-12.773914,"median":-7.253346,"eighty":-5.800175,"marketCap":246207962},{"date":"2025-03-14","current":-0.930199,"twenty":-12.763183,"median":-7.144044,"eighty":-5.763741,"marketCap":226770492},{"date":"2025-03-21","current":-0.770737,"twenty":-12.752113,"median":-7.105005,"eighty":-5.687956,"marketCap":187895550},{"date":"2025-03-28","current":-0.730871,"twenty":-12.743752,"median":-7.036301,"eighty":-5.574632,"marketCap":178176815},{"date":"2025-04-04","current":-0.564099,"twenty":-12.730087,"median":-6.998128,"eighty":-5.417311,"marketCap":137520105},{"date":"2025-04-11","current":-0.476129,"twenty":-12.580434,"median":-6.945391,"eighty":-5.374404,"marketCap":116074096},{"date":"2025-04-17","current":-0.41859,"twenty":-12.352677,"median":-6.926527,"eighty":-5.321594,"marketCap":102046721},{"date":"2025-04-25","current":-0.497989,"twenty":-12.291873,"median":-6.904742,"eighty":-1.375231,"marketCap":121403202},{"date":"2025-05-02","current":-0.511809,"twenty":-12.245663,"median":-6.881395,"eighty":-1.223405,"marketCap":124772347},{"date":"2025-05-09","current":-0.423699,"twenty":-12.15573,"median":-6.846375,"eighty":-1.1893,"marketCap":103292222},{"date":"2025-05-16","current":-0.417316,"twenty":-12.148314,"median":-6.834702,"eighty":-1.12879,"marketCap":107691766},{"date":"2025-05-23","current":-0.449909,"twenty":-12.121955,"median":-6.75723,"eighty":-1.07488,"marketCap":116102658},{"date":"2025-05-30","current":-0.450473,"twenty":-12.120637,"median":-6.747152,"eighty":-1.061679,"marketCap":116248231},{"date":"2025-06-06","current":-0.507762,"twenty":-12.041995,"median":-6.685868,"eighty":-1.033834,"marketCap":131031991},{"date":"2025-06-13","current":-0.562731,"twenty":-11.924033,"median":-6.5954,"eighty":-0.989998,"marketCap":145217284},{"date":"2025-06-20","current":-0.488895,"twenty":-11.91238,"median":-6.57789,"eighty":-0.951354,"marketCap":126163379},{"date":"2025-06-27","current":-0.501055,"twenty":-11.897527,"median":-6.552046,"eighty":-0.939895,"marketCap":129301288},{"date":"2025-07-03","current":-0.51497,"twenty":-11.882746,"median":-6.531197,"eighty":-0.932192,"marketCap":132892092},{"date":"2025-07-11","current":-0.664396,"twenty":-11.845391,"median":-6.513687,"eighty":-0.915408,"marketCap":171452797},{"date":"2025-07-18","current":-1.071809,"twenty":-11.813935,"median":-6.466558,"eighty":-0.901766,"marketCap":276588946},{"date":"2025-07-25","current":-1.435347,"twenty":-11.800172,"median":-6.430581,"eighty":-0.91143,"marketCap":370402741},{"date":"2025-08-01","current":-1.228506,"twenty":-11.772648,"median":-6.345689,"eighty":-0.913154,"marketCap":317025927},{"date":"2025-08-08","current":-1.05869,"twenty":-11.733327,"median":-6.279953,"eighty":-0.915408,"marketCap":266884071},{"date":"2025-08-15","current":-1.015014,"twenty":-11.717599,"median":-6.27111,"eighty":-0.917957,"marketCap":255873774},{"date":"2025-08-22","current":-1.053558,"twenty":-11.711701,"median":-6.248553,"eighty":-0.922507,"marketCap":265590500},{"date":"2025-08-29","current":-1.130648,"twenty":-11.697847,"median":-6.240161,"eighty":-0.927824,"marketCap":285023951},{"date":"2025-09-05","current":-1.047134,"twenty":-11.691098,"median":-6.234271,"eighty":-0.929873,"marketCap":263971046},{"date":"2025-09-12","current":-1.066407,"twenty":-11.688352,"median":-6.217154,"eighty":-0.931528,"marketCap":268829408},{"date":"2025-09-19","current":-1.00859,"twenty":-11.674168,"median":-6.167847,"eighty":-0.932308,"marketCap":254254320},{"date":"2025-09-26","current":-1.092103,"twenty":-11.654686,"median":-6.150338,"eighty":-0.934175,"marketCap":275307225},{"date":"2025-10-03","current":-1.143496,"twenty":-11.648787,"median":-6.138654,"eighty":-0.935832,"marketCap":288262860},{"date":"2025-10-10","current":-1.252707,"twenty":-11.625195,"median":-6.129234,"eighty":-0.937276,"marketCap":315793582},{"date":"2025-10-17","current":-1.143496,"twenty":-11.585874,"median":-6.098338,"eighty":-0.939018,"marketCap":288262860},{"date":"2025-10-24","current":-1.483976,"twenty":-11.573312,"median":-6.085275,"eighty":-0.940658,"marketCap":374093936},{"date":"2025-10-31","current":-1.882272,"twenty":-11.535481,"median":-6.072715,"eighty":-0.944448,"marketCap":474500101},{"date":"2025-11-07","current":-1.768195,"twenty":-11.493728,"median":-6.047595,"eighty":-0.950132,"marketCap":417819201},{"date":"2025-11-14","current":-1.902139,"twenty":-11.492838,"median":-5.97813,"eighty":-0.950743,"marketCap":449469716},{"date":"2025-11-21","current":-1.668791,"twenty":-11.473837,"median":-5.972235,"eighty":-0.95386,"marketCap":394330309},{"date":"2025-11-28","current":-1.583937,"twenty":-11.438475,"median":-5.963003,"eighty":-0.958453,"marketCap":374279615},{"date":"2025-12-05","current":-1.608686,"twenty":-11.3991,"median":-5.921482,"eighty":-0.963621,"marketCap":380127734},{"date":"2025-12-12","current":-1.488688,"twenty":-11.349949,"median":-5.869128,"eighty":-0.966191,"marketCap":351772572},{"date":"2025-12-19","current":-1.236978,"twenty":-11.209123,"median":-5.84706,"eighty":-0.976733,"marketCap":292294118},{"date":"2025-12-26","current":-1.301703,"twenty":-11.180579,"median":-5.82548,"eighty":-0.977791,"marketCap":307588578},{"date":"2026-01-02","current":-1.28732,"twenty":-10.823503,"median":-5.782265,"eighty":-0.97889,"marketCap":304189809},{"date":"2026-01-09","current":-1.675673,"twenty":-10.734234,"median":-5.771277,"eighty":-0.987831,"marketCap":395956567},{"date":"2026-01-16","current":-1.531839,"twenty":-10.632004,"median":-5.730809,"eighty":-0.990132,"marketCap":361968879},{"date":"2026-01-23","current":-1.510263,"twenty":-10.51228,"median":-5.690707,"eighty":-0.994023,"marketCap":356870726},{"date":"2026-01-30","current":-1.474305,"twenty":-10.431808,"median":-5.626838,"eighty":-0.999937,"marketCap":348373804},{"date":"2026-02-06","current":-1.409579,"twenty":-10.281677,"median":-5.512839,"eighty":-1.00602,"marketCap":333079344},{"date":"2026-02-13","current":-2.337313,"twenty":-10.17329,"median":-5.423912,"eighty":-1.009395,"marketCap":552299933},{"date":"2026-02-20","current":-2.502722,"twenty":-10.087087,"median":-5.390906,"eighty":-1.011964,"marketCap":591385774},{"date":"2026-02-27","current":-2.553064,"twenty":-9.944314,"median":-5.374404,"eighty":-1.018277,"marketCap":603281465},{"date":"2026-03-06","current":-2.157519,"twenty":-9.899493,"median":-5.330396,"eighty":-1.027437,"marketCap":509815323},{"date":"2026-03-13","current":-2.258203,"twenty":-9.891226,"median":-5.316643,"eighty":-1.03397,"marketCap":533606704},{"date":"2026-03-20","current":-1.848275,"twenty":-9.844641,"median":-2.553064,"eighty":-1.034185,"marketCap":436741793},{"date":"2026-03-26","current":-1.797933,"twenty":-9.780792,"median":-2.509914,"eighty":-1.034219,"marketCap":424846102}],"updateTime":1774684535993},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NMRA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2581220067","title":"Neumora Therapeutics Unveils Pipeline Advancements Targeting Major Brain Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2581220067","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581220067?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:23","pubTimestamp":1762431839,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc. has released a corporate presentation outlining its progress in neuroscience drug development. The company highlighted a broad pipeline targeting major indications, including major depressive disorder, Alzheimer's disease agitation, schizophrenia, obesity, Parkinson's disease, and ALS. Key programs include Navacaprant, a KOR antagonist for major depressive disorder, currently progressing toward pivotal data readouts; NMRA-511, a V1aR antagonist for agitation in Alzheimer's disease; and two M4 modulators, NMRA-861 and NMRA-898, for schizophrenia. The pipeline also features NMRA-215, an NLRP3 inhibitor for obesity and Parkinson's disease, as well as additional candidates targeting Parkinson's disease and ALS. Several clinical milestones are expected over the next year as the company advances its portfolio. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intell","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL8dHqn4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2581067228","title":"Neumora Therapeutics Q3 EPS $(0.35) Misses $(0.33) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581067228","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581067228?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:22","pubTimestamp":1762431723,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.33) by 4.79 percent. This is a 22.22 percent increase over losses of $(0.45) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48682814/neumora-therapeutics-q3-eps-0-35-misses-0-33-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA"],"gpt_icon":0},{"id":"2581906774","title":"Neumora Therapeutics Inc - on-Track to Report Data From Phase 1B Study of Nmra-511 in Alzheimer's Disease Agitation Around Year End","url":"https://stock-news.laohu8.com/highlight/detail?id=2581906774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581906774?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430407,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA4RZKPF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2581067785","title":"Neumora Therapeutics Inc -  Expects Cash, Cash Equivalents & Marketable Securities as of Sept 30, 2025, Will Fund Operating Plan Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2581067785","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581067785?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430407,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA4RZKPF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2581060866","title":"Neumora Therapeutics Inc - Drawn Additional $40 Mln From Existing Venture Debt Facility With K2 Healthventures","url":"https://stock-news.laohu8.com/highlight/detail?id=2581060866","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581060866?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:00","pubTimestamp":1762430407,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUA4RZKPF:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2580297374","title":"Neumora Therapeutics to Join Stifel Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2580297374","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580297374?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:00","pubTimestamp":1762171242,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc will participate in the Stifel 2025 Healthcare Conference with a fireside chat on Wednesday, November 12, 2025, at 2:00 p.m. ET in New York, NY. The event will be webcast live on the company's website, with a replay available for 30 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire  on November 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL2q9TVk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SF","BK4112","BK4007","LU0314104364.USD","LU2095319765.USD","LU2210149790.SGD","BK4588","NDAQ","BK4127","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4585","LU2210150020.SGD","NMRA","IE00BGHQF748.EUR","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2580412995","title":"Neumora Therapeutics Inc  expected to post a loss of 33 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580412995","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580412995?lang=en_us&edition=fundamental","pubTime":"2025-11-01 06:32","pubTimestamp":1761949924,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc  expected to post a loss of33cents a share - Earnings Preview Neumora Therapeutics Inc NMRA.OQ NMRA.O is expected to  show no change in quarterly revenue when it reports  resu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nL8N3WC2KE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2579992150","title":"Major Stakeholders Make Bold Moves in Neumora Therapeutics!","url":"https://stock-news.laohu8.com/highlight/detail?id=2579992150","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579992150?lang=en_us&edition=fundamental","pubTime":"2025-10-30 10:02","pubTimestamp":1761789775,"startTime":"0","endTime":"0","summary":"New insider activity at Neumora Therapeutics, Inc. ( ($NMRA) ) has taken place on October 29, 2025. Director Kristina Burow and significant shareho...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-stakeholders-make-bold-moves-in-neumora-therapeutics-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-stakeholders-make-bold-moves-in-neumora-therapeutics-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2579153237","title":"Neumora Director Kristina Burow Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2579153237","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579153237?lang=en_us&edition=fundamental","pubTime":"2025-10-30 07:23","pubTimestamp":1761780187,"startTime":"0","endTime":"0","summary":"Kristina Burow, Managing Director, reported the acquisition of common shares of Neumora Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL7DzBMl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Neumora Director Kristina Burow Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2579153447","title":"ARCH Venture Partners X Reports Acquisition of Neumora Therapeutics Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2579153447","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579153447?lang=en_us&edition=fundamental","pubTime":"2025-10-30 07:20","pubTimestamp":1761780011,"startTime":"0","endTime":"0","summary":"ARCH Venture Partners X, LLC reported the acquisition of common shares of Neumora Therapeutics Inc. . The Form 4 filing was submitted by multiple reporting owners, including ARCH Venture Fund XII, L.P., ARCH VII, L.P., and Robert Nelsen, among other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 29, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL8GQ1tQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2579308970","title":"Guggenheim upgrades Neumora Therapeutics, Inc. (NMRA) to a Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2579308970","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579308970?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:36","pubTimestamp":1761737777,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Yatin Suneja upgraded Neumora Therapeutics, Inc. to a Buy on October 27 and set a price target of $14.00. The company’s shares c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-upgrades-neumora-therapeutics-inc-nmra-to-a-buy-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-upgrades-neumora-therapeutics-inc-nmra-to-a-buy-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NMRA"],"gpt_icon":0},{"id":"2578956057","title":"Neumora Therapeutics price target raised to $8 from $6 at Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2578956057","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578956057?lang=en_us&edition=fundamental","pubTime":"2025-10-28 19:56","pubTimestamp":1761652561,"startTime":"0","endTime":"0","summary":"Needham raised the firm’s price target on Neumora Therapeutics (NMRA) to $8 from $6 and keeps a Buy rating on the shares. The firm is more positive...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-price-target-raised-to-8-from-6-at-needham-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-price-target-raised-to-8-from-6-at-needham-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NMRA"],"gpt_icon":0},{"id":"2578646452","title":"Neumora Therapeutics Raised to Buy From Neutral by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2578646452","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578646452?lang=en_us&edition=fundamental","pubTime":"2025-10-27 20:29","pubTimestamp":1761568140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NMRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 27, 2025 08:29 ET (12:29 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA"],"gpt_icon":0},{"id":"2578012643","title":"Neumora Therapeutics' Potential Obesity Drug Shows Weight Loss in Preclinical Mice Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2578012643","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578012643?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:56","pubTimestamp":1761566216,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics  said it received positive preclinical data from three studies with mice for its potential obesity drug NMRA-215.The drug showed weight loss of up to 19% as a monotherapy with semaglutide-like induction and 26% in combination with semaglutide, the company said.Chief Executive and Chairman Paul Berns said the data \"reinforce our conviction that NMRA-215 may be an effective, next-generation, oral treatment for obesity.\"Shares of the company were up 1.1% in recent premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2578643692","title":"Neumora Therapeutics Begins Dosing Study of Investigational Schizophrenia Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2578643692","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578643692?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:42","pubTimestamp":1761565333,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics  said Monday it has launched a phase 1 single ascending dose and multiple ascending dose study of its investigational schizophrenia treatment NMRA-898.The study will evaluate the safety, tolerability, and human pharmacokinetic impact of the drug, the company said.The company said it expects to provide an update for NMRA-898 and another candidate, NMRA-861, within its M4 schizophrenia franchise by mid-2026.Shares of the company were up more than 1% in recent premarket activity Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2578648675","title":"Neumora Therapeutics initiates Phase 1 clinical study of NMRA-988","url":"https://stock-news.laohu8.com/highlight/detail?id=2578648675","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578648675?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:10","pubTimestamp":1761563456,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics (NMRA) announced the initiation of a Phase 1 single-ascending dose/multiple-ascending dose study of NMRA-898. Neumora’s M4 fra...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-initiates-phase-1-clinical-study-of-nmra-988-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-initiates-phase-1-clinical-study-of-nmra-988-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2578103296","title":"BRIEF-Neumora Therapeutics Announces Initiation Of Phase 1 Clinical Study Of M4 Positive Allosteric Modulator NMRA-898","url":"https://stock-news.laohu8.com/highlight/detail?id=2578103296","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578103296?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:02","pubTimestamp":1761562926,"startTime":"0","endTime":"0","summary":"BRIEF-Neumora Therapeutics Announces Initiation Of Phase 1 Clinical Study Of M4 Positive Allosteric Modulator NMRA-898Oct 27 (Reuters) - Neumora Therapeutics Inc NMRA.O:NEUMORA THERAPEUTICS ANNOUNCES ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nTUA2NVS88:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2578610814","title":"Neumora Therapeutics Inc - Plans M4 Franchise Update by Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2578610814","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578610814?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:00","pubTimestamp":1761562801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nTUA2NVS88:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NMRA"],"gpt_icon":0},{"id":"2578610811","title":"Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator Nmra-898","url":"https://stock-news.laohu8.com/highlight/detail?id=2578610811","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578610811?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:00","pubTimestamp":1761562801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nTUA2NVS88:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NMRA","BK4007"],"gpt_icon":0},{"id":"2578361033","title":"Neumora Reports Positive Preclinical Results for NMRA-215","url":"https://stock-news.laohu8.com/highlight/detail?id=2578361033","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578361033?lang=en_us&edition=fundamental","pubTime":"2025-10-27 18:58","pubTimestamp":1761562716,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics, Inc. ( ($NMRA) ) has provided an update. On October 27, 2025, Neumora Therapeutics announced positive preclinical results for...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neumora-reports-positive-preclinical-results-for-nmra-215?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neumora-reports-positive-preclinical-results-for-nmra-215?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NMRA","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":66,"code":"91000000","status":"200"}]}}